ES2361269T3 - Anticuerpos especificos de tgf beta 1. - Google Patents

Anticuerpos especificos de tgf beta 1. Download PDF

Info

Publication number
ES2361269T3
ES2361269T3 ES06750860T ES06750860T ES2361269T3 ES 2361269 T3 ES2361269 T3 ES 2361269T3 ES 06750860 T ES06750860 T ES 06750860T ES 06750860 T ES06750860 T ES 06750860T ES 2361269 T3 ES2361269 T3 ES 2361269T3
Authority
ES
Spain
Prior art keywords
antibody
binding
tgf
image12
tgf beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06750860T
Other languages
English (en)
Spanish (es)
Inventor
Julian Davies
Craig Duane Dickinson
Lihua Huang
Bryan Edward Jones
David Matthew Marquis
Scott William Rowlinson
Ying Tang
Peter Edward Vaillancourt
Jeffry Dean Watkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2361269T3 publication Critical patent/ES2361269T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
ES06750860T 2005-04-22 2006-04-20 Anticuerpos especificos de tgf beta 1. Expired - Lifetime ES2361269T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67408205P 2005-04-22 2005-04-22
US674082P 2005-04-22

Publications (1)

Publication Number Publication Date
ES2361269T3 true ES2361269T3 (es) 2011-06-15

Family

ID=37192643

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06750860T Expired - Lifetime ES2361269T3 (es) 2005-04-22 2006-04-20 Anticuerpos especificos de tgf beta 1.

Country Status (23)

Country Link
US (2) US7619069B2 (https=)
EP (1) EP1874818B1 (https=)
JP (1) JP5070200B2 (https=)
KR (1) KR100978684B1 (https=)
CN (1) CN101163719A (https=)
AT (1) ATE505489T1 (https=)
AU (1) AU2006240056B2 (https=)
BR (1) BRPI0608376A8 (https=)
CA (1) CA2607448C (https=)
CY (1) CY1111518T1 (https=)
DE (1) DE602006021292D1 (https=)
DK (1) DK1874818T3 (https=)
EA (1) EA016038B1 (https=)
ES (1) ES2361269T3 (https=)
HR (1) HRP20110334T1 (https=)
IL (1) IL186775A (https=)
NO (1) NO20076003L (https=)
PL (1) PL1874818T3 (https=)
PT (1) PT1874818E (https=)
RS (1) RS51845B (https=)
SI (1) SI1874818T1 (https=)
UA (1) UA93201C2 (https=)
WO (1) WO2006116002A2 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009296937B2 (en) * 2008-09-29 2015-02-12 Centocor Ortho Biotech Inc. Anti-CD147 antibodies, methods, and uses
AU2009316387B2 (en) * 2008-11-22 2015-01-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8685932B2 (en) * 2008-12-16 2014-04-01 Option Pharmaceuticals, Llc Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases
CA3159253A1 (en) 2009-01-09 2010-07-15 Seagen Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
US9289513B2 (en) 2011-03-23 2016-03-22 Option Pharmaceuticals, Llc Targeted cytokine for treatment of musculoskeletal diseases
SG195253A1 (en) * 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
WO2013134365A1 (en) 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
US10259626B2 (en) 2012-03-08 2019-04-16 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
PT3107573T (pt) * 2014-02-19 2019-01-10 Merck Patent Gmbh Imunoterapia com il-12 visada ao cancro
EP3244926B8 (en) 2015-01-14 2024-08-21 The Brigham and Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
JP2019511911A (ja) 2016-02-17 2019-05-09 ノバルティス アーゲー Ｔｇｆベータ２抗体
WO2017143451A1 (en) * 2016-02-26 2017-08-31 Western University Anti-cd11d antibodies and uses thereof
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
WO2017201036A1 (en) 2016-05-17 2017-11-23 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
JP7632835B2 (ja) * 2016-05-20 2025-02-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 加齢関連疾患及び症状の遺伝子治療法
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
WO2018043734A1 (en) * 2016-09-05 2018-03-08 Chugai Seiyaku Kabushiki Kaisha Anti-tgf-beta 1 antibodies and methods of use
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2019045086A1 (ja) * 2017-08-29 2019-03-07 林化成株式会社 活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
ES2984919T3 (es) 2017-11-06 2024-10-31 Hoffmann La Roche Procedimientos diagnósticos y terapéuticos para el cáncer
CN112739717B (zh) 2018-06-29 2025-02-11 璟尚生物制药公司 三特异性拮抗剂
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
KR102885113B1 (ko) 2018-10-18 2025-11-13 머크 샤프 앤드 돔 엘엘씨 항-rsv 항체의 제제 및 그의 사용 방법
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
AR117918A1 (es) 2019-01-30 2021-09-01 Scholar Rock Inc COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS
US10851157B2 (en) 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
US20230057012A1 (en) 2020-01-11 2023-02-23 Scholar Rock, Inc. Tgfb inhibitors and use thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
AU2022294100A1 (en) * 2021-06-18 2024-02-01 Genzyme Corporation Anti-tgf-beta antibody formulations and their use
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
WO2000040227A2 (en) 1999-01-05 2000-07-13 University Of Utah Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1620128A1 (en) 2003-04-30 2006-02-01 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
EP1765400A2 (en) 2004-06-04 2007-03-28 Genentech, Inc. Method for treating lupus
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties

Also Published As

Publication number Publication date
CA2607448A1 (en) 2006-11-02
KR100978684B1 (ko) 2010-08-31
US20100040633A1 (en) 2010-02-18
ATE505489T1 (de) 2011-04-15
JP5070200B2 (ja) 2012-11-07
IL186775A (en) 2013-03-24
WO2006116002A9 (en) 2007-07-19
KR20070114220A (ko) 2007-11-29
UA93201C2 (ru) 2011-01-25
WO2006116002A2 (en) 2006-11-02
AU2006240056A1 (en) 2006-11-02
RS51845B (sr) 2012-02-29
JP2008538564A (ja) 2008-10-30
DE602006021292D1 (de) 2011-05-26
EA016038B1 (ru) 2012-01-30
CA2607448C (en) 2014-11-18
HRP20110334T1 (hr) 2011-06-30
US8128927B2 (en) 2012-03-06
CN101163719A (zh) 2008-04-16
CY1111518T1 (el) 2015-08-05
WO2006116002A3 (en) 2007-02-01
US20080050375A1 (en) 2008-02-28
IL186775A0 (en) 2008-02-09
DK1874818T3 (da) 2011-06-14
PT1874818E (pt) 2011-05-05
BRPI0608376A2 (pt) 2010-11-16
NO20076003L (no) 2008-01-22
AU2006240056B2 (en) 2012-02-16
BRPI0608376A8 (pt) 2018-10-16
EP1874818B1 (en) 2011-04-13
EA200702278A1 (ru) 2008-08-29
EP1874818A2 (en) 2008-01-09
PL1874818T3 (pl) 2011-09-30
SI1874818T1 (sl) 2011-08-31
US7619069B2 (en) 2009-11-17

Similar Documents

Publication Publication Date Title
ES2361269T3 (es) Anticuerpos especificos de tgf beta 1.
ES2633810T3 (es) Proteínas de unión a antígeno humanas que se unen a beta-Klotho, receptores de FGF y complejos de los mismos
ES3009462T3 (en) Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
ES2713505T3 (es) Anticuerpos anti-TGF-beta modificados genéticamente y fragmentos de unión a antígeno
ES2893148T3 (es) Anticuerpos contra el receptor alfa de la interleucina 4 canina
ES3036151T3 (en) Human cgrp receptor binding antibodies
ES2881642T3 (es) Anticuerpos anti-pro-miostatina/miostatina latente y usos de los mismos
ES2384176T3 (es) Anticuerpos anti-miostatina
JP5058261B2 (ja) 抗ミオスタチン抗体
JP2017031176A (ja) 脳疾患を治療するための抗タウｐＳ４２２抗体の使用
ES2291626T3 (es) Anticuerpos humanos de ligando anti-hfas antagonista y fragmentos asociados.
JP2025523049A (ja) 抗Ｎｅｃｔｉｎ－４抗体及びその使用
ES2665851T3 (es) Nuevo anticuerpo anti-CTGF humano
CN114853890B (zh) 一种prlr抗原结合蛋白及其制备方法和应用
CN113637070A (zh) 抗spike蛋白的抗体或抗原结合片段及其应用
ES2566343T3 (es) Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos
US8207307B2 (en) Antibodies against human CCN1 and uses thereof
CN113637083A (zh) 用于治疗冠状病毒的融合蛋白及其应用
HK1119183A (en) Tgf beta 1 specific antibodies
HK40084128A (en) Coronavirus antibody and use thereof
BR122019020863B1 (pt) Ácido nucleico, vetor de expressão, microrganismo transgênico e método de produção de uma proteína de ligação a antígeno
PT103452A (pt) Polipéptidos que se ligam especificamente ao domínio ed-b de fibronectina com sequências especiais